Rilotumumab, formerly referred to as AMG 102, is a monoclonal antibody primarily utilized as a significant laboratory tool to probe the processes driving neoplastic expansion . Such compound specifically targets the insulin-like growth factor 1 receptor , a major driver in various tumorous forms.

Andecaliximab, also known as GS-5745, represents a valuable investigative instrument within the field of immunological investigations . This humanized monoclonal protein selectively binds to CD40 ligand (CD40L), a crucial molecule involved in inflammatory responses. By inhibiting CD40L engagement